Literature DB >> 1290266

Burn wound closure using permanent skin replacement materials.

R G Tompkins1, J F Burke.   

Abstract

Over the past decade, very significant advances in the development of clinically useful, permanent skin replacement materials have taken place. The most prominent and successful approaches to the physiological closure of an open wound have been either by creating a totally artificial dermal matrix material, by using culture techniques to expand cell populations for autologous transplantation, or by using a combination of these methods. As a result of substantial early progress in this field, permanent skin replacement materials as a treatment modality promise significant contributions to improved wound management and increased survival rates for patients with devastating soft tissue destruction such as massive burn injuries.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1290266     DOI: 10.1007/bf02067114

Source DB:  PubMed          Journal:  World J Surg        ISSN: 0364-2313            Impact factor:   3.352


  38 in total

1.  Use of cultured epidermal autografts and dermal allografts as skin replacement after burn injury.

Authors:  C Cuono; R Langdon; J McGuire
Journal:  Lancet       Date:  1986-05-17       Impact factor: 79.321

2.  Human epidermal cell cultures: growth and differentiation in the absence of differentiation in the absence of dermal components or medium supplements.

Authors:  M Eisinger; J S Lee; J M Hefton; Z Darzynkiewicz; J W Chiao; E de Harven
Journal:  Proc Natl Acad Sci U S A       Date:  1979-10       Impact factor: 11.205

3.  Coverage of full skin thickness burns with allograft inoculated with autogenous epithelial cells.

Authors:  Z R Gao; Z Q Hao; L J Nie; G F Liu
Journal:  Burns Incl Therm Inj       Date:  1986-02

4.  Grafting of burn patients with allografts of cultured epidermal cells.

Authors:  J M Hefton; M R Madden; J L Finkelstein; G T Shires
Journal:  Lancet       Date:  1983-08-20       Impact factor: 79.321

5.  Characterization of cellular elements in healed cultured keratinocyte autografts used to cover burn wounds.

Authors:  M J Petersen; B Lessane; D T Woodley
Journal:  Arch Dermatol       Date:  1990-02

6.  Living tissue formed in vitro and accepted as skin-equivalent tissue of full thickness.

Authors:  E Bell; H P Ehrlich; D J Buttle; T Nakatsuji
Journal:  Science       Date:  1981-03-06       Impact factor: 47.728

7.  Wound tissue can utilize a polymeric template to synthesize a functional extension of skin.

Authors:  I V Yannas; J F Burke; D P Orgill; E M Skrabut
Journal:  Science       Date:  1982-01-08       Impact factor: 47.728

8.  Artificial dermis for major burns. A multi-center randomized clinical trial.

Authors:  D Heimbach; A Luterman; J Burke; A Cram; D Herndon; J Hunt; M Jordan; W McManus; L Solem; G Warden
Journal:  Ann Surg       Date:  1988-09       Impact factor: 12.969

9.  Reconstitution of structure and cell function in human skin grafts derived from cryopreserved allogeneic dermis and autologous cultured keratinocytes.

Authors:  R C Langdon; C B Cuono; N Birchall; J A Madri; E Kuklinska; J McGuire; G E Moellmann
Journal:  J Invest Dermatol       Date:  1988-11       Impact factor: 8.551

10.  Composite skin graft: frozen dermal allografts support the engraftment and expansion of autologous epidermis.

Authors:  E L Heck; P R Bergstresser; C R Baxter
Journal:  J Trauma       Date:  1985-02
View more
  2 in total

Review 1.  Burns (Part 2). Tops and flops using cultured epithelial autografts in children.

Authors:  M Meuli; M Raghunath
Journal:  Pediatr Surg Int       Date:  1997-09       Impact factor: 1.827

2.  Amniotic fluid stem cells provide considerable advantages in epidermal regeneration: B7H4 creates a moderate inflammation microenvironment to promote wound repair.

Authors:  Qing Sun; Fang Li; Hong Li; Rui-Hua Chen; Yan-Zheng Gu; Ying Chen; Han-Si Liang; Xin-Ran You; Si-Si Ding; Ling Gao; Yun-Liang Wang; Ming-De Qin; Xue-Guang Zhang
Journal:  Sci Rep       Date:  2015-06-23       Impact factor: 4.379

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.